Archive · 6 Jun 2025
New Breast Cancer Treatment Shows Promising Results in Trial
Imagine a special medicine like a smart bomb that targets cancer cells.
This new medicine is for a type of breast cancer called HER2-positive metastatic breast cancer.
This cancer grows because of too much of a protein.
The new medicine combines a targeting antibody with chemotherapy to go directly into the cancer cells and kill them.
In a study, this medicine helped patients live longer without their cancer getting worse, compared to the usual treatment.
The medicine lowered the risk of the cancer spreading and disappearing for some people.
Doctors are now planning to show the results to the government so it can be used as a first choice of treatment.
A new treatment for HER2-positive metastatic breast cancer shows promising results.
The new approach combines an antibody with a chemotherapy drug, targeting cancer cells directly.
The trial showed a 44% risk reduction in disease progression or death compared to the standard treatment.
The median progression-free survival was significantly improved with the new treatment.
The results will be submitted to regulatory bodies for potential approval as a first-line treatment.
- Who
- Researchers and patients in a global trial.
- What
- A new treatment for HER2-positive metastatic breast cancer showed improved outcomes in a clinical trial.
- When
- The results were presented at the annual meeting of the American Society for Clinical Oncology. Data from the trial spans 2.5 years.
- Where
- Global trial, led by Dana-Farber Cancer Institute
- Why
- To find a more effective first-line treatment for HER2-positive metastatic breast cancer.
Standard of Care
New Treatment (T-DXd)
Treatment Approach
Standard of Care
The standard of care, known as THP, combines chemotherapy with two antibodies.
New Treatment (T-DXd)
The new treatment uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug.
Progression-Free Survival
Standard of Care
Median progression-free survival of 26.9 months
New Treatment (T-DXd)
Median progression-free survival of 40.7 months
- Type of Cancer
- HER2-positive metastatic breast cancer
- Percentage of Breast Cancer Cases
- 15-20%
- New Treatment
- Trastuzumab deruxtecan (T-DXd)
- Treatment Method
- Antibody combined with chemotherapy drug
- Risk Reduction
- 44%
- Median Progression-Free Survival (New Treatment)
- 40.7 months
- Median Progression-Free Survival (Standard Treatment)
- 26.9 months